Short answer
Thermo Fisher Scientific (TMO) filed an 8-K current report with the SEC on July 23, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 fiscal 2026 results announced for quarter ended June 27, 2026.
Thermo Fisher Scientific 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 fiscal 2026 results announced for quarter ended June 27, 2026
- Full financial results and management commentary furnished in Exhibit 99.1
- Results furnished under Item 2.02, limiting their treatment as filed information under Exchange Act Section 18
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue rose 10% to $11.99B, including 5% organic growth, signaling broadening customer demand across end markets
- Adjusted EPS increased 13% to $6.03, while adjusted operating margin expanded to 22.8% from 21.9%
- GAAP operating margin improved to 17.4% from 16.9%, with operating income up 14% to $2.09B
- Six-month free cash flow reached $2.50B versus $1.48B, supporting acquisitions, debt management and shareholder returns
- $1.0B quarterly stock repurchase and microbiology divestiture indicate continued portfolio reshaping and capital deployment discipline
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Thermo Fisher Scientific 8-K filings
Get the next TMO 8-K as it lands
Follow TMO for push alerts, or ask the research agent what this filing means.